Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMED6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,663
Award facts
- Contract value 100% obligated
- $49,662.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $49,662.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, was structured as a firm fixed-price contract with no set-aside designation, indicating the contractor competed successfully in an unrestricted procurement environment. This award is issued under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract with the Defense Logistics Agency, a $499.9 billion strategic initiative designed to streamline pharmaceutical procurement for Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and SAM registration since 2001 to support military healthcare operations. The company maintains a comprehensive product portfolio encompassing branded and generic pharmaceuticals, biologics, specialty medications, and medical consumables, with demonstrated performance across numerous prior delivery orders issued by the DLA's Medical Supply Chain division. This particular delivery order for Entyvio, a biologic medication used in gastroenterology and immunology treatment, reflects the contractor's ongoing capability to fulfill the specialized pharmaceutical requirements of the Department of Defense's global medical system.
Quick answers
Who was awarded contract SPE2DR26FMED6?
SPE2DR26FMED6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FMED6 worth?
The government has obligated $49,663 on SPE2DR26FMED6.
Is contract SPE2DR26FMED6 an order under another contract?
Yes. SPE2DR26FMED6 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMED6 competed?
The extent of competition for SPE2DR26FMED6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award